Form 4: ICAD Inc. Director Andy Sassine Acquires Stock Options in Lieu of Cash Fees

Director Andy Sassine acquired 27,586 stock options in ICAD Inc. on August 15, 2024, in lieu of quarterly cash director fees.

Summary

• On August 15, 2024, Andy Sassine, a director of ICAD Inc., acquired 27,586 stock options.
• These options were granted in lieu of quarterly cash director fees.
• The exercise price of the options is $1.49.
• The options are immediately exercisable and expire on August 15, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, aligning director interests with shareholders and conserving cash. This is generally viewed positively.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Granting options in lieu of cash fees conserves the company's cash resources.

Management Comments

• This option has been granted in lieu of quarterly cash director fees.
• The option is immediately exercisable on the date of grant.

Industry Context

Directors receiving stock options is a common practice to align their interests with shareholders and conserve company cash.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in many publicly traded companies, including those in the medical technology sector like ICAD Inc.
• Companies such as Hologic and Varex Imaging also use stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's performance.
• The company benefits from conserving cash by granting options instead of cash fees.

Key Dates